论文部分内容阅读
目的研究分析阿替普酶急诊静脉溶栓治疗超早期急性脑梗死20例临床效果。方法选取我院2012年至2014年收治的20例超早期急性脑梗死患者,应用阿替普酶急诊静脉溶栓治疗,观察分析患者的治疗效果和安全性。结果以上20例患者中,15例痊愈,4例好转,1例死亡,治愈率达到了75%。结论对于急性超早期脑梗死患者,实行阿替普酶静脉溶栓治疗具有显著的疗效,安全性较高,可以明显改善患者的神经功能缺损症状,值得推广应用。
Objective To study the clinical effect of intravenous thrombolytic therapy of alteplase in treating 20 cases of ultra-early acute cerebral infarction. Methods Twenty patients with early-stage acute cerebral infarction admitted from 2012 to 2014 in our hospital were treated with intravenous thrombolytic therapy of alteplase, and the therapeutic effect and safety were observed and analyzed. Results Of the above 20 patients, 15 recovered, 4 improved and 1 died, with a cure rate of 75%. Conclusion For patients with acute super-early cerebral infarction, intravenous thrombolytic therapy with alteplase has significant curative effect and high safety, which can obviously improve the symptoms of patients with neurological deficits and is worth popularizing and applying.